Objective: The aim of this study was to determine the effect of Hydroxyurea on adverse clinical events and haematological indices in paediatric patients with sickle cell anaemia.
INTRODUCTION
Sickle Cell Anaemia (SCA) is the most important potentially devastating, recessively inherited condition. SCA is characterized by haemoglobin (Hb) polymerisation that results in sickleshaped red blood cells, vaso-occlusion, haemolysis and vasculo-endothelial dysfunction, causing pain, anaemia, organ injury, and early mortality. Disease severity varies widely but overall mortality is substantially increased and life expectancy decreased when compared with the general population. Despite the well-described genetics and pathophysiology of SCA, clinical care for affected individuals has been mostly supportive, typically including intravenous hydration, analgesics, antibiotics and red blood cell transfusions.
Clinical symptoms begin in the first year of life with the physiologic decline in fetal haemoglobin (HbF) concentration, but higher levels of HbF have been associated with fewer pain crises (1) and improved survival (2) . Hydroxyurea, an antineoplastic agent that inhibits ribonucleotide reductase, increases HbF in red blood cells and has other potentially beneficial effects, including improved nitric oxide metabolism, reduced red cell-endothelial interaction and decreased erythrocyte density (3) . Hydroxyurea is the only widely used drug, which modifies disease pathogenesis.
The most recent evidence supporting the use of Hydroxyurea in children comes from the Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG). This was a multi-center, randomized, double-blind placebo-controlled study of daily oral Hydroxyurea in children with SCA (HbSS and Sß0 thalassemia) 9 to 18 months of age. There were significantly clinical events in the Hydroxyurea group including painful events, acute chest syndrome (ACS), hospitalizations, and transfusions. Based on the results of the BABY HUG trial, the authors concluded that Hydroxyurea could be considered for paediatric patients (4).
The Hydroxyurea Study of Long Term Effects (HUSTLE) is a prospective observational study of children with SCA treated with Hydroxyurea based on clinical severity, which attempts to evaluate the long-term cellular and molecular effects of Hydroxyurea. Reports have not identified any evidence of cumulative chromosomal damage in the Hydroxyurea-exposed group with up to 12 years of treatment exposure (5) . In addition, extended follow-up from a small teenage cohort from HUSOFT (with 14-years of treatment since infancy) indicated good health, normal growth and development, and no evidence of myelodysplasia or malignancy (6) .
The hematological effects of Hydroxyurea therapy are closely linked to clinical benefits, but also are the parameters used for dose escalation to maximum tolerated dose. Laboratory effects include a predictable rise in the hemoglobin concentration, HbF percentage, and mean corpuscular volume along with a concurrent decrease in absolute reticulocyte count, total leukocyte count, and absolute neutrophil count. These laboratory values, in addition to examination of the peripheral blood film for erythrocyte morphology, are used to escalate patients to maximum tolerated dose, and also can be used to monitor medication adherence (7).
These laboratory effects have been demonstrated to be consistent and sustainable in both adults and children with SCA (8, 9) . Hydroxyurea in an attempt to reduce the number of hospitalizations for disease-related events.
Although Hydroxyurea is widely available in our setting, there are dosing limitations. It is only available as a 500mg capsule preparation and the recommended daily dose in children is 20-30mg/kg/day, therefore to ensure that patients get an adequate dose alternate day dosing is required in many cases. No studies have yet been done in our population however to determine the outcome of this intervention or to assess the impact on clinical status.
The aim of this study was to determine the effect of Hydroxyurea therapy on adverse clinical events and haematological indices in paediatric patients with sickle cell anaemia attending the Paediatric Haematology Clinic at EWMSC.
Method
The study is a retrospective cohort study. It compares the same cohort of patients before and Adverse clinical events included known complications of sickle cell anaemia, such as painful events, dactylitis, acute chest syndrome, stroke, priapism, sepsis/bacteraemia and osteomyelitis.
The haematological indices investigated were haemoglobin concentration, mean corpuscular volume, mean corpuscular haemoglobin, white blood cell, neutrophil count, platelet count, and reticulocyte count.
The mean and standard deviation (SD) were used to summarise continuous normally distributed variables, while the median and interquartile range (IQR) were used for skewed variables. The rate ratio (RR) was used to compare the pre and post-treatment incidence rate of events; RR estimates and their 95% confidence intervals were derived in a Poisson regression model using the robust clustered estimator of variance. The paired t-test was used to test the mean difference in haematologic indices between pairs of time points.
Ethics approvals were obtained from The University of the West Indies and the North Central Regional Health Authority.
Results
Of the 280 patients with sickle cell anaemia attending clinic 50 were on Hydroxyurea, 40 (80%) met the study criteria. The median age at initiation of treatment was 7 years (IQR 6; range 3 to 15). 22 (55.0%) were male and 18 (45%) were female. 32 (80.0%) were HbSS, 5 (12.5%) were HbSC and 3 (7.5%) were HbSβ Thalassemia. Mean haemoglobin concentration at baseline was 7.7 g/dL (SD 1.0). The average dose of Hydroxyurea was 21 mg/kg (SD 4). 11 (27.5%) children were on an alternating day regimen (500mg every other day or 500mg alternating with 1000mg daily) while 29 (72.5%) were on a daily regimen. Table 1) . Post-treatment, the incidence rate of painful crises managed at home, requiring emergency department care or requiring admission to the ward were 79% (RR 0.21; 95% CI 0.11, 0.40), 81% (RR 0.19; 95% CI 0.06, 0.56) and 84% (RR 0.16; 95% CI 0.09, 0.28) lower than their respective pre-treatment incidence rates. There was no evidence at the 5% level that the treatment effect of HU on the overall rates of painful crises (p=0.223), or on the rate of painful crises requiring home (p=0.162), emergency room (p=0.592) or ward care (p=0.991) was different in those on a daily and on alternating day regimens of HU. Table 2 compares the pre-and post-treatment incidence rates, expressed per 18 person-years of follow-up, of the rarer events associated with of sickle cell anaemia. While the rates of these rarer events were generally observed to be lower post-treatment, there was no statistical evidence of any significant differences. measured at baseline and then at 1, 3, 6, 12 and 24 months after starting HU (Table 3) . Table 3 : Mean of each haematologic index at each time point after initiation of treatment Table 4 shows the increment and time to apparent stabilisation of changes in each of the There was no significant change in platelet count in this cohort of patients. 
DISCUSSION
The primary objective of this study was to compare clinical events in patients before and after
Hydroxyurea therapy. The results demonstrated that the incidence rate of painful crises posttreatment was significantly reduced with Hydroxyurea in all settings, which is in keeping with the literature. This has important implications on the quality of life of patients and parents.
Recurrent pain from sickle cell disease can be a significant and disabling problem (10) .
Interestingly, the results also indicated that the treatment effect of Hydroxyurea on the overall rates of painful crises was similar in those on a daily and on alternating day regimens of the drug in all settings. This is particularly important since to our knowledge, there have been no previous studies using alternate day dosing of Hydroxyurea or detailed studies of pharmacokinetic behavior of Hydroxyurea. This lends support to continued use of Hydroxyurea in our local setting with the limitation of the 500mg capsule presentation. Rarer clinical adverse events had a higher incidence rate of the event pre-treatment than post-treatment but with no significant difference. This may be due to the small numbers in the study cohort or the need for longer follow up.
The incidence rate of top-up transfusions, however, appeared to be similar pre-and posttreatment. In the pivotal randomized trial upon which the FDA based its approval of Hydroxyurea, adult patients taking Hydroxyurea were found to require fewer transfusions than those who were not on Hydroxyurea (11) . This would be the expected trend in children as well and perhaps if this cohort was followed for a longer period the outcome may have been different.
From the results obtained it was clear that the laboratory efficacy of Hydroxyurea became evident during the first to sixth months of treatment and the benefits were then sustained when children with SCA were adherent with therapy. There were significant increases in haemoglobin, MCV and MCHC with decreases in WBC, ANC, ARC, and reticulocyte percentage while the platelet count remained relatively stable throughout the follow up period. Of note, no patients experienced severe neutropenia or thrombocytopenia requiring dose adjustment or discontinuation of Hydroxyurea on either dosing regimen. All patients on Hydroxyurea currently have complete blood counts done every 3 to 6 months after the initial few months of treatment. Given the results of this study this may no longer be deemed necessary.
In conclusion the effect of Hydroxyurea therapy in our population was similar to that found in the literature. There was a significant decrease in the incidence of painful crises once therapy was initiated and this was evident with daily dosing as well as alternate day dosing. There was no significant decrease in the incidence of any other adverse clinical events. No patients in the cohort experienced severe neutropenia or thrombocytopenia requiring dose adjustment or discontinuation of Hydroxyurea. The vast majority of available evidence on the efficacy, effectiveness and safety of Hydroxyurea in childhood SCA is from high-income countries and for children with high quality supportive care. The conclusions drawn from this study would be useful in guiding Hydroxyurea use in other less developed countries with limited resources.
